Cyclacel says cash on hand enough to last "beyond" pivotal sapacitabine trial

Cyclacel Pharmaceuticals (CYCC) announces Q3 results and says it expects its $35M in cash to be enough to last through the completion of SEAMLESS (that's sapacitabine in AML), which is near the 50% enrollment mark.

The company also reminds investors that primary outcomes from sapacitabine in MDS (Phase 2) will be reported at ASH.

R&D for the quarter comes in at $4.6M, up sharply thanks (in part) to manufacturing costs for SEAMLESS.

CYCC also plans (in the next 12 months) to: "Announce registration-directed, clinical development plan for sapacitabine in MDS after treatment failure of hypomethylating agents [and] report updated data from the Phase 1 study of sapacitabine and seliciclib in patients with advanced solid tumors, including BRCA carriers." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs